These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report. Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747 [TBL] [Abstract][Full Text] [Related]
6. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications. Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874 [TBL] [Abstract][Full Text] [Related]
7. [Erysipeloid cutaneous leishmaniasis: about a clinical observation]. El kartouti A; Elbenaye J; Miloudi M Pan Afr Med J; 2015; 21():54. PubMed ID: 26405490 [TBL] [Abstract][Full Text] [Related]
8. Old-world leishmaniasis of the auricle. Skevas A; Kastanioudakis I; Bai M; Kostoula A Lancet; 1997 Jan; 349(9044):28-9. PubMed ID: 8988123 [No Abstract] [Full Text] [Related]
9. A double-blind randomized clinical trial of a topical herbal extract (Z-he) vs. systemic meglumine antimonate. Momeni AZ; Aminjavaheri M Int J Dermatol; 2000 Nov; 39(11):880. PubMed ID: 11123462 [No Abstract] [Full Text] [Related]
10. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B. Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547 [No Abstract] [Full Text] [Related]
11. Oriental sore: a case report. Asvesti C; Anastassiadis G; Kolokotronis A; Zographakis I Oral Surg Oral Med Oral Pathol; 1992 Jan; 73(1):56-8. PubMed ID: 1603565 [TBL] [Abstract][Full Text] [Related]
12. Leishmaniasis of the lip. Veraldi S; Rigoni C; Gianotti R Acta Derm Venereol; 2002; 82(6):469-70. PubMed ID: 12575860 [No Abstract] [Full Text] [Related]
13. Use of meglumine antimoniate in canine leishmaniasis. Lamothe J Vet Rec; 2004 Mar; 154(12):378. PubMed ID: 15074332 [No Abstract] [Full Text] [Related]
14. [Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate]. Rodrigues AM; Hueb M; Santos TA; Fontes CJ Rev Soc Bras Med Trop; 2006; 39(2):139-45. PubMed ID: 16699638 [TBL] [Abstract][Full Text] [Related]
15. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Moosavi Z; Nakhli A; Rassaii S Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282 [No Abstract] [Full Text] [Related]
16. Intralesional injections of meglumine antimoniate to treat complex facial leishmania infantum acquired in Spain: a case report. Mostmans Y; Van Gysel J; Vanden Nest H; Mervillie K; Richert B; Clevenbergh P J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e548-e550. PubMed ID: 35181939 [No Abstract] [Full Text] [Related]
17. Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico. Vargas-Gonzalez A; Canto-Lara SB; Damian-Centeno AG; Andrade-Narvaez FJ Am J Trop Med Hyg; 1999 Dec; 61(6):960-3. PubMed ID: 10674678 [TBL] [Abstract][Full Text] [Related]
18. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device. Bogenrieder T; Lehn N; Landthaler M; Stolz W Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089 [TBL] [Abstract][Full Text] [Related]